Catherijne A. J. Knibbe
Leiden University
282 Papers
849 Citations
Catherijne A. J. Knibbe is an academic researcher from Leiden University. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 49, co-authored 242 publications. Previous affiliations of Catherijne A. J. Knibbe include Erasmus University Medical Center & Utrecht University.
Chat about Author
Papers
The pharmacokinetics of caffeine in preterm newborns : no influence of doxapram but important maturation with age
Aline G.J. Engbers,Aline G.J. Engbers,Swantje Völler,Christian F Poets,Catherijne A. J. Knibbe,Irwin K M Reiss,Birgit C. P. Koch,Robert B. Flint,Robert B. Flint,Sinno H.P. Simons +9 more
TL;DR: In this article, the authors examined whether there is a drug-drug interaction between doxapram and caffeine by developing a population PK model for preterm infants, including infants with and without doxaspram treatment.
Defining off-label and unlicensed use of medicines for children: results of a Delphi survey.
Antje Neubert,Ian C. K. Wong,Alessandro Bonifazi,Mariana Catapano,Mariagrazia Felisi,Paola Baiardi,Carlo Giaquinto,Catherijne A. J. Knibbe,Miriam C. J. M. Sturkenboom,Maisoon Abdullah Ghaleb,Adriana Ceci +10 more
TL;DR: The Delphi panel agreed that the definitions for unlicensed and off-label drug use in children should be circulated within the scientific community and recommended to be adopted by relevant regulatory authorities.
Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults
Anne van Rongen,Margreke J. E. Brill,Margreke J. E. Brill,Janelle D. Vaughns,Pyry A. J. Välitalo,Eric P.A. van Dongen,Bert van Ramshorst,Jeffrey S. Barrett,Johannes N. van den Anker,Catherijne A. J. Knibbe +9 more
TL;DR: Higher midazolam clearance in obese adolescents is hypothesise by less obesity-induced suppression of CYP3A activity, while the increase with WTexcess is explained by increased liver blood flow.
Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine.
Isabelle Kohler,Thomas Hankemeier,Piet H. van der Graaf,Catherijne A. J. Knibbe,J. G. Coen van Hasselt +4 more
TL;DR: How novel treatment individualization biomarkers can be identified using a clinical metabolomics-based approach is discussed, and how concepts inspired from the field of PK-PD modeling can be integrated in this process in order to increase the clinical relevance of identified biomarkers and precision medicine.